Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…
TRENDS
Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
To read the full story
Related Article
TRENDS
- Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
- Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
- Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
- 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
- Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…